anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

227,701-227,760 of 319,975

filter-aware
12
Waterfall plot and spider plot showing patient-level clinical outcomes.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
13
The slide uses a before-after comparison for three specific patients (15B-01, 15B-15, 15B-17) to demonstrate clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
14
Includes a comparison table of historical data vs ELAHARE and a specific VIRO-15 clinical outcome table.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
15
The slide uses a bar chart to compare efficacy metrics (RECIST1.1, CA-125, PFS-6-month) across various clinical studies, with Genelux's VIRO-15 trial highlighted.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
16
The slide outlines a clinical trial protocol, specifically a randomized open-label study comparing an experimental arm to an active comparator arm.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
17
Includes Kaplan-Meier survival curves and patient cohort descriptions for two separate study groups.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
18
Includes specific patient case reports with RECIST criteria and biomarker data.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
19
Includes a bio for Benny Li, CEO of Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
20
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
21
The slide highlights the synergy between two existing therapies (TVI and Olvi-Vec) to create a new modality.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
22
The slide uses a hub-and-spoke style layout to categorize strategic pillars.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
23
The slide uses a combination of a bulleted list and a hub-and-spoke style visual representation of facility locations.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
24
The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
25
The slide highlights key competitive moats including patent counts, freedom to operate, and regulatory protections.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
26
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
27
Includes specific footnotes regarding market close date, cash reporting date, and PIPE commitment details.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
28
The slide uses a dual-track visual: a list for past milestones and two curved arrows for future milestones.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
29
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
30
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
31
The slide lists key clinical advisors, highlighting their leadership roles in major oncology organizations and clinical trials.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
32
The slide uses two distinct chart types (spaghetti plot and waterfall plot) to validate the efficacy of the treatment.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
33
Includes a patient profile, a bar chart comparing PFS across treatment lines, and a longitudinal line chart tracking tumor size and CA-125 levels.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
34
Includes patient-specific histological evidence (Pt.#15A-01 and Pt.#15A-11) demonstrating the mechanism of action.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
35
The slide uses histology images and HALO infiltration histograms to demonstrate the mechanism of action and clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
36
The slide uses a combination of clinical timeline, patient history, and immunological data (ELISPOT) to correlate T-cell response with clinical outcome.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
37
The slide uses clinical study data (VIRO-15, NCT01443260) to validate the mechanism of action.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
01
Slide 1
GMS | Results Presentation Deck | 20 slidesGMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
02
GMS | Results Presentation Deck | 20 slidesGMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
03
Includes a table of net sales by product, a pie chart of sales mix, and bulleted financial highlights.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
04
GMS | Results Presentation Deck | 20 slidesGMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
05
GMS | Results Presentation Deck | 20 slidesGMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
06
GMS | Results Presentation Deck | 20 slidesGMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
07
The slide uses a combination of bar charts for absolute values and line charts for margin percentages to illustrate financial performance.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
08
Includes financial metrics for Q324 and historical cash usage for FY21-23.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
09
Includes a footnote regarding selling days and the Kamco transaction.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
10
Includes footnotes regarding selling days, Kamco transaction, and reconciliation of non-GAAP metrics.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
11
GMS | Results Presentation Deck | 20 slidesGMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
12
Includes operational metrics like business days and branch counts alongside standard income statement line items.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
13
Includes supplemental disclosures and a reconciliation for free cash flow.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
14
The table includes two distinct sections: one by growth driver (Organic, Acquisitions, Fx Impact) and one by product segment (Wallboard, Ceilings, Steel Framing, Complementary Products).GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
15
Includes detailed adjustments (A-H) with corresponding commentary.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
16
The table covers 2017 through 3Q24 LTM.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
17
The slide provides a standard financial reconciliation for non-GAAP measures.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
18
Includes a commentary section explaining specific adjustment categories (A-E).GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
19
Includes footnotes detailing unamortized discounts and deferred financing costs.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
20
Includes a note regarding selling days and the exclusion of the Kamco transaction.GMS | Results Presentation Deck | 20 slides · GMS
Conference presentation Investor relations 1 hit
01
Slide 1
Gogoro | Investor Presentation Deck | 29 slidesGogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations 1 hit
02
The slide contains headshots and titles for the CEO and CFO.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations 1 hit
03
Includes footer with company name and page number.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations 1 hit
04
Gogoro | Investor Presentation Deck | 29 slidesGogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations 1 hit
05
GGR is the ticker symbol for Gogoro Inc.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations 1 hit
06
The slide acts as a visual summary of recent business momentum.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations 1 hit
07
The slide serves as a thematic transition or cover page for the investor presentation.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations Beat · Problem1 hit
08
PGBN stands for Powered by Gogoro Network.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations Beat · Problem1 hit
09
The image shows Gogoro electric scooters branded for the Tainan City Police Department, despite the text referencing Taipei.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations Beat · Problem1 hit
10
The slide details a partnership to transition delivery fleets to electric, citing specific metrics like 20% current green delivery share and a 40% target by 2026.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
11
Includes photos of the manufacturing line and the product launch event for the Gogoro CrossOver.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
12
SIDBI is a major Indian financial institution; this slide serves as a credibility signal.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
13
The image serves as a visual metaphor for the massive addressable market of two-wheelers in India, implying the need for electrification.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
14
The slide serves as a visual anchor for the company's core product offering.Gogoro | Investor Presentation Deck | 29 slides · Gogoro
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit